Abstract
Lung cancer is characterized as a series of genetic mutations and epigenetic modifications, resulting in the silencing of tumor suppressor genes and activating of tumorigenic genes. In this review, we will explore those lung cancer–related genes that undergo significant epigenetic modifications. These genes include CDKN2A, DAPK, RASSF1A, FHIT, CHD13, DAL1, APC, RUNX3, CDH1, TSLC1, and PTEN. We will discuss the role of epigenetic modifications used as diagnostic biomarkers and therapeutic predictive biomarkers in lung cancer. The epigenetics of lung cancer have been widely studied in recent years. It will improve our understanding about lung cancer early detection and personalized treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
